Irinotecan Medicus (Irinotecan Hydrochloride Trihydrate)

• Irinotecan Medicus is employed in oncology protocols targeting DNA replication pathways in malignant disease.
• Metastatic colorectal cancer: improves overall survival when used in combination chemotherapy regimens.
• Colorectal adenocarcinoma: provides tumor control in advanced disease stages.
• Other solid tumors: may be incorporated into approved treatment protocols for selected tumor types.

• Irinotecan Hydrochloride Trihydrate is a pro‑drug converted intracellularly to SN‑38, which binds to the DNA‑topoisomerase I complex. This binding prevents the religation step of DNA replication, resulting in permanent single‑strand breaks, replication arrest, and ultimately apoptosis of rapidly dividing cancer cells.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Diarrhea: often severe and may require antidiarrheal therapy.
• Neutropenia: reduced white blood cell count increasing infection risk.
• Nausea and vomiting: may be managed with antiemetics.
• Alopecia: temporary hair loss during treatment.
• Fatigue: generalized tiredness affecting daily activities.
• Abdominal cramping: discomfort in the gastrointestinal tract.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophil count requiring urgent care.
• Severe colitis (including ileitis): inflammation of the colon that can be life‑threatening.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.
• Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis in rare cases.

Before initiating therapy, clinicians should assess patient suitability and monitor for known risks.

• Baseline blood counts: obtain complete blood count to detect pre‑existing cytopenias.
• Liver function: evaluate hepatic enzymes as irinotecan metabolism is hepatic.
• UGT1A1 genotype: consider testing for reduced enzyme activity that may increase toxicity.
• Concomitant myelosuppressive agents: adjust dosing or schedule to avoid excessive bone‑marrow suppression.
• Pregnancy and lactation: avoid use due to unknown fetal risk; discontinue if pregnancy occurs.
• Store at ambient temperature: keep in original container, protect from light and moisture, and do not freeze.

Irinotecan interacts with several drug classes that may alter its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase irinotecan exposure.
• UGT1A1 inhibitors (e.g., atazanavir): can raise SN‑38 levels and toxicity.
• Concurrent high‑dose irinotecan formulations: risk of cumulative toxicity.

Moderate Interactions (Monitor Closely)

• Other myelosuppressive agents (e.g., carboplatin): monitor blood counts closely.
• Anticoagulants (e.g., warfarin): increased bleeding risk with mucosal injury.
• Antidiarrheal agents (e.g., loperamide): may mask early signs of severe diarrhea.
• CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect.
• Herbal supplements affecting liver enzymes (e.g., St. John’s wort): monitor for altered drug levels.